ISO/TR 10993-22:2017-07 (E)

Biological evaluation of medical devices - Part 22: Guidance on nanomaterials

Contents

Page

Foreword v

Introduction vi

1 Scope 1

2 Normative references 2

3 Termsanddefinitions 2

4 General principles 5
4.1 General considerations 5
4.2 Biological evaluation of nanomaterials 6
4.3 Categorization of nanomaterials 6
4.4 Nanomaterial equivalence 8

5 Characterization of nanomaterials 8
5.1 General considerations 8
5.2 Characterization parameters and methods 10
5.3 Use of reference materials 14

6 Sample preparation 15
6.1 General considerations 15
6.2 Special considerations for nanostructured materials 15
6.3 Special considerations for nano-objects 15
6.4 Identity, storage and stability of stock nanomaterials 17
6.5 Description of chemical composition of stock and dosing dispersions 17
6.6 Characterization of stock dispersions 18
6.7 Characterization of dosing solutions prepared from stock dispersions 18
6.8 Dose metrics 19
6.9 Additional considerations 19
6.9.1 Endotoxin 19
6.9.2 Sterilization 20

7 Release of nano-objects from medical devices 21
7.1 General considerations 21
7.2 Degradation products 22
7.3 Release of nano-objects by wear 22
7.4 In situ processing 22

8 Toxicokinetics 22
8.1 General considerations 22
8.2 Factors influencing the toxicokinetics 23
8.2.1 Physicochemical properties 23
8.2.2 Biomolecular adsorption 24
8.2.3 Exposure route 25
8.2.4 Dose 25
8.2.5 Species and gender 25
8.2.6 Measurement techniques 26

9 Toxicological evaluation 26
9.1 General considerations 26

9.2 In vitro cytotoxicity testing ... 27
9.2.1 General considerations ... 27
9.2.2 Consideration of nanomaterial interference with the assays ... 28
9.2.3 Consideration of relevant dose and dose metrics ... 28
9.2.4 Consideration of nano-object kinetics ... 28
9.3 Genotoxicity, carcinogenicity and reproductive toxicity ... 29
9.3.1 General considerations ... 29
9.3.2 In vitro genotoxicity tests ... 30
9.3.3 In vivo genotoxicity tests ... 31
9.3.4 Carcinogenicity ... 32
9.3.5 Reproductive toxicity ... 32
9.4 Immunotoxicity, irritation and sensitization ... 33
9.4.1 General considerations ... 33
9.4.2 Immunotoxicity ... 33
9.4.3 Sensitization ... 34
9.4.4 Irritation ... 35
9.5 Haemocompatibility ... 36
9.5.1 General considerations ... 36
9.5.2 Complement system activation ... 37
9.5.3 Specific considerations for haemocompatibility testing ... 37
9.6 Systemic toxicity ... 37
9.7 Pyrogenicity ... 38
9.8 Implantation ... 39

10 Presentation of characterization and test results ... 39

11 Risk assessment ... 40
11.1 General considerations ... 40
11.2 Exposure assessment ... 42
11.3 Biological hazard identification ... 43
11.4 Risk estimation ... 44
11.5 Risk evaluation ... 44

12 Biological evaluation report ... 44

Bibliography ... 46